Literature DB >> 2145322

Failure of T cell receptor-anti-CD3 monoclonal antibody interaction in T cells from marrow recipients to induce increases in intracellular ionized calcium.

M Yamagami1, P W McFadden, S M Koethe, V Ratanatharathorn, L G Lum.   

Abstract

There are multiple immune defects in T cells from recipients after bone marrow transplantation (BMT). This study examines recipient T cells for increases in intracellular ionized calcium concentration [( Ca2+]i) after binding the T cell receptor-CD3 complex with anti-CD3 MAb. PBL from 10 of 23 short-term recipients (less than 1 yr after BMT) responded poorly (less than 35% of control) to anti-CD3 stimulation and PBL from 9 of 23 had blunted calcium flux responses (35-70% of control). Purified CD2+, CD56- cells from seven additional short-term recipients including three autologous marrow recipients were closely examined, and a sizable proportion of CD3+ cells from six of seven recipients did not increase [Ca2+]i after anti-CD3 stimulation. The decreased magnitude of the responses was due to decreased numbers of responding cells and not to a decrease in mean CD3 fluorescent intensity or in calcium flux responses on a single cell basis. Five of seven long-term recipients (greater than 1 yr after BMT) had PBL that responded normally and two of seven had PBL with blunted calcium flux responses. The data show that the signal transduction response mediated by the CD3-antigen receptor as measured by calcium flux is defective early after autologus or allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145322      PMCID: PMC296869          DOI: 10.1172/JCI114845

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

Review 2.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

3.  A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation.

Authors:  B E Bierer; S J Burakoff; B R Smith
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

4.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

5.  The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies.

Authors:  B Perussia; G Trinchieri; A Jackson; N L Warner; J Faust; H Rumpold; D Kraft; L L Lanier
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

6.  Prominent expansion of circulating lymphocytes bearing gamma T-cell receptors, with preferential expression of variable gamma genes after allogeneic bone marrow transplantation.

Authors:  E Vilmer; F Triebel; V David; C Rabian; M Schumpp; G Leca; L Degos; T Hercend; F Sigaux; A Bensussan
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

7.  Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.

Authors:  S C Meuer; R E Hussey; D A Cantrell; J C Hodgdon; S F Schlossman; K A Smith; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor.

Authors:  S C Meuer; O Acuto; R E Hussey; J C Hodgdon; K A Fitzgerald; S F Schlossman; E L Reinherz
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

9.  T lymphocyte characteristics in bone marrow-transplanted patients. II. Analysis with monoclonal antibodies.

Authors:  H G de Bruin; A Astaldi; T Leupers; R J van de Griend; L J Dooren; P T Schellekens; H J Tanke; M Roos; J M Vossen
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

10.  HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor.

Authors:  G P Linette; R J Hartzman; J A Ledbetter; C H June
Journal:  Science       Date:  1988-07-29       Impact factor: 47.728

View more
  4 in total

1.  Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Emily M Goren; Patricia A Taylor; Scott N Mueller; Heather E Stefanski; Mark J Osborn; Hamish S Scott; Elena A Komarova; Andrei V Gudkov; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

2.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

3.  Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Steven L Highfill; Angela Panoskaltsis-Mortari; Patricia A Taylor; Richard L Boyd; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

4.  Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.

Authors:  K Sugita; Y Nojima; K Tachibana; R J Soiffer; C Murray; S F Schlossman; J Ritz; C Morimoto
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.